Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NeuroSense Therapeutics Ltd. Warrant (NRSNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: NRSNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.45% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.6 | 52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 |
52 Weeks Range 0.10 - 1.06 | Updated Date 06/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.94 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -159.5% | Return on Equity (TTM) -2478.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11925007 |
Shares Outstanding - | Shares Floating 11925007 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NeuroSense Therapeutics Ltd. Warrant
Company Overview
History and Background
NeuroSense Therapeutics Ltd. is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for neurodegenerative diseases. The warrants give the holder the right to purchase shares of the company's common stock at a specified price within a specific period. Information is limited on specific milestones for the warrant itself, its value depends on the value of the common stock.
Core Business Areas
- Drug Development: Development of therapeutics for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and Parkinson's disease.
Leadership and Structure
Details about NeuroSense's executive team and organizational structure can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- PrimeC: NeuroSense's leading drug candidate, PrimeC, is in clinical development for ALS. As a development-stage therapy, PrimeC currently has no revenue. The ALS treatment market has competitors such as Amylyx Pharmaceuticals (AMYX), Biogen (BIIB), and Mitsubishi Tanabe Pharma.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, particularly in the neurodegenerative disease space. Drug development is capital-intensive and high-risk, with long regulatory approval timelines.
Positioning
NeuroSense is a smaller player in the neurodegenerative disease market, competing against larger, more established pharmaceutical companies. Their competitive advantage depends on the success of PrimeC and other pipeline candidates.
Total Addressable Market (TAM)
The ALS market alone is estimated to be worth billions of dollars. NeuroSense's position is tied to their clinical success and ability to capture market share from existing therapies.
Upturn SWOT Analysis
Strengths
- Promising drug candidate (PrimeC) in clinical development
- Focus on unmet medical needs in neurodegenerative diseases
- Experienced management team in drug development
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- High risk of drug development failure
Opportunities
- Positive clinical trial results could lead to significant market value increase
- Partnerships with larger pharmaceutical companies for drug development and commercialization
- Expansion of pipeline with new drug candidates
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from other companies developing treatments for neurodegenerative diseases
- Patent disputes and intellectual property challenges
- Difficulty in raising capital to fund ongoing clinical trials
Competitors and Market Share
Key Competitors
- AMYX
- BIIB
- MTLKY
Competitive Landscape
NeuroSense faces intense competition from larger pharmaceutical companies with more resources. Success hinges on clinical trial outcomes and securing partnerships. Market share information is difficult to quantify for a pre-revenue company such as NeuroSense. Market share percentages are approximate and represent overall market share in the neurodegenerative disease therapeutic area.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited given the company's pre-revenue stage. Growth is measured in terms of advancement in the pipeline and securing funding.
Future Projections: Future growth is contingent on the successful development and commercialization of PrimeC and other pipeline candidates. Analyst projections depend on these factors.
Recent Initiatives: Recent initiatives include ongoing clinical trials for PrimeC and efforts to secure additional funding and partnerships.
Summary
NeuroSense Therapeutics is a clinical-stage biopharmaceutical company focusing on developing treatments for neurodegenerative diseases. The company's success is highly dependent on the clinical success of PrimeC, its leading drug candidate. The company has a promising drug candidate, but the small financial resources and high risk of drug development are considerable challenges. Investors should monitor clinical trial results, partnership agreements, and financial stability carefully. The NeuroSense Therapeutics Ltd. Warrant value is tied to the performance of the NeuroSense Therapeutics Ltd. stock.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial professional. Market share data is approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NeuroSense Therapeutics Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-12-09 | Co-Founder, CEO & Director Mr. Alon Ben-Noon | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.neurosense-tx.com |
Full time employees 17 | Website https://www.neurosense-tx.com | ||
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.